Ipca Labs partners with BioSimilar Sciences for US biosimilar tech transfer

Ipca Laboratories Ltd. (Ipca) and BioSimilar Sciences PR LLC (BSS) announced a definitive Technology Transfer and Joint Development Agreement. This collaboration will shift late-stage development, clinical manufacture, and commercial supply of Ipca's next-generation anti-cancer/anti-inflammatory monoclonal antibody biosimilar to BSS's campus in Aguadilla, Puerto Rico. This initiative targets the US market, currently valued over $4 bn and projected to grow at a 12% AGR, aiming to create US jobs and secure the supply chain for essential medicines.

The agreement involves multi-million dollar private investment, leveraging OcyonBio’s 60 million units of sterile filling capacity annually. This "Made in the USA" strategy is expected to create hundreds of high-paying jobs in Puerto Rico and reduce reliance on Asian and European supply chains. The first BSS biosimilar is slated for launch in 2027, with new molecule targets aiming for 2028/29 FDA approval.

Ipca will receive defined milestone fees for Know-how/Technology transfer and royalties on net sales upon commercialization. The deal covers exclusive license territory for the USA and Canada, and non-exclusive for some LATAM countries, focusing on joint clinical development, full tech transfer, and commercial manufacturing and launch.